Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranimustine
- Development stage
- Phase 3
- Lead developer
- Mitsubishi Tanabe
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Ranimustine is a nitrosourea alkylating agent used primarily in Japan for the treatment of chronic myelogenous leukemia and polycythemia vera. It acts by alkylating and cross-linking DNA strands in tumor cells, thereby inhibiting their proliferation and growth. The drug is also used as part of combination chemotherapy regimens for certain lymphomas and has been investigated in clinical trials for other cancers. Developed by Mitsubishi Tanabe Pharma, ranimustine is administered intravenously or orally depending on the regimen[1][2][3][7]. Its mechanism of action involves DNA damage through alkylation and cross-linking[1][7].
- Brand names
- CymerinCymerine
- Other names
- ranimustinaranomustineRANIMUSTINE (MART.)Ranimustinum1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)ureaGlucopyranoside, methyl-6-(3-(2-chloroethyl)-3-nitrosoureido)-6-deoxy-, alpha-D-
02
Targets
DNA
Beyond the preview
Go deeper on ranimustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranimustine.